VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy.

Autor: Bosco J; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA., Zhou Z; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA., Gabriëls S; argenx BVBA, Zwijnaarde, Belgium., Verma M; Stem Cell Institute, Paul and Sheila Wellstone Muscular Dystrophy Center, Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA., Liu N; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA., Miller BK; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA., Gu S; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA., Lundberg DM; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA., Huang Y; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA., Brown E; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA., Josiah S; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA., Meiyappan M; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA., Traylor MJ; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA., Chen N; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA., Asakura A; Stem Cell Institute, Paul and Sheila Wellstone Muscular Dystrophy Center, Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA., De Jonge N; argenx BVBA, Zwijnaarde, Belgium., Blanchetot C; argenx BVBA, Zwijnaarde, Belgium., de Haard H; argenx BVBA, Zwijnaarde, Belgium., Duffy HS; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA., Keefe D; Shire Human Genetic Therapies, a Takeda company, Lexington, MA, USA.

Publikováno v: Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2021 Mar 23; Vol. 21, pp. 369-381. Date of Electronic Publication: 2021 Mar 23 (Print Publication: 2021).

Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases.

Autor: Martini PG; Department of Protein Expression and Purification Research, Shire Human Genetic Therapies Inc, 700 Main Street, Cambridge, MA 02139, USA. pmartini@shire.com, Cook LC, Alderucci S, Norton AW, Lundberg DM, Fish SM, Langsetmo K, Jönsson G, Lood C, Gullstrand B, Zaleski KJ, Savioli N, Lottherand J, Bedard C, Gill J, Concino MF, Heartlein MW, Truedsson L, Powell JL, Tzianabos AO

Publikováno v: BMC immunology [BMC Immunol] 2010 Aug 20; Vol. 11, pp. 43. Date of Electronic Publication: 2010 Aug 20.